FAQ

vidofludimus

Known as: 2-(3-fluoro-3'-methoxybiphenyl-4-carbamoyl)cyclopent-1-enecarboxylic acid, 4SC-101 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2018
012320102018

Related topics

Related topics

2 relations

Broader (2)

Biphenyl CompoundsDicarboxylic Acids

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
vidofludimus
Dicarboxylic Acids
Biphenyl Compounds

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Review article: novel oral-targeted therapies in inflammatory bowel disease.
BACKGROUND There is a great unmet clinical need for efficacious, tolerable, economical and orally administrated drugs for the… (More)
Is this relevant?
2013
2013
Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
BACKGROUND Vidofludimus (SC12267) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH) and the… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2013
Review
2013
Inhibition of IL-17 as a pharmacological approach for IBD.
Several experimental approaches have been utilized, in order to critically examine the roles of IL-17 family members in… (More)
Is this relevant?
2012
2012
Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action.
Vidofludimus (Vido) is a novel oral immunomodulatory drug that inhibits dihydro-orotate dehydrogenase and lymphocyte… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Immunosuppression with 4SC-101, a novel inhibitor of dihydroorotate dehydrogenase, in a rat model of renal transplantation.
BACKGROUND 4SC-101 is a novel dihydroorotate dehydrogenase inhibitor and a blocker of interleukin (IL)-17 secretion with… (More)
Is this relevant?
Review
2012
Review
2012
Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis
This review identifies possible pharmacological targets for inflammatory bowel disease (IBD) within the IL-23/IL-17 axis… (More)
  • figure 1
  • figure 2
Is this relevant?
2010
2010
New preclinical findings with vidofludimus.
  • Immunotherapy
  • 2010
 
Is this relevant?
2010
2010
4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease.
BACKGROUND Dihydroorotate dehydrogenase (DHODH) is a key enzyme involved in pyrimidine biosynthesis. DHODH is a known target for… (More)
Is this relevant?
2010
2010
4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.
Immunosuppressive treatments of systemic lupus (SLE) remain associated with significant toxicities; hence, compounds with better… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?